Cytokinetics to Hold Annual Meeting of Stockholders
May 13 2015 - 4:00PM
SOUTH SAN FRANCISCO,
Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated
(Nasdaq:CYTK) announced today that its Annual Meeting of
Stockholders will be held on Wednesday, May 20, 2015 at 10:30 AM
Pacific Time at the Embassy Suites Hotel, located at 250 Gateway
Boulevard in South San Francisco, CA. Robert I. Blum, President and
Chief Executive Officer, is scheduled to present an overview of
Cytokinetics' performance.
Interested parties may access the live audio webcast of this
presentation and replay by visiting the Investor Relations section
of the Cytokinetics website at www.cytokinetics.com. The live
conference call may also be accessed by dialing (866) 999-CYTK
(2985) (United States and Canada) or (706) 679-3078 (international)
and typing in the passcode 34785263. The webcast will be available
via Cytokinetics' website for one week following the
event. The replay of the audiocast will be available via
telephone from May 20, 2015 at 1:30 PM Pacific Time until May 27,
2015 by dialing (855) 859-2056 (United States and Canada) or (404)
537-3406 (international) and typing in the passcode
34785263.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused
on the discovery and development of novel small molecule
therapeutics that modulate muscle function for the potential
treatment of serious diseases and medical conditions. Cytokinetics
is developing tirasemtiv, a fast skeletal
muscle activator, as a potential treatment for amyotrophic lateral
sclerosis (ALS). Tirasemtiv has been granted
orphan drug designation and fast track status by the U.S. Food and
Drug Administration and orphan medicinal product designation by the
European Medicines Agency for the potential treatment of ALS.
Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a cardiac muscle activator, for the
potential treatment of heart failure. Cytokinetics is collaborating
with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal
muscle activator, for the potential treatment of spinal muscular
atrophy. Amgen holds an exclusive license worldwide to develop and
commercialize omecamtiv mecarbil and Astellas
holds an exclusive license worldwide to develop and commercialize
CK-2127107. Both licenses are subject to Cytokinetics' specified
development and commercialization participation rights. All of
these drug candidates have arisen from Cytokinetics' muscle biology
focused research activities and are directed towards the
cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human
cell. Additional information about Cytokinetics can be obtained at
http://www.cytokinetics.com/.
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to planned presentations, and the
properties and potential benefits of Cytokinetics' drug candidates
and potential drug candidates. Such statements are based on
management's current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the
development, testing, regulatory approval and production of
Cytokinetics' drug candidates and potential drug candidates that
could slow or prevent clinical development or product approval,
including risks that current and past results of clinical trials or
preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and
other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange
Commission.
CONTACT: Cytokinetics, Incorporated
Joanna L. Goldstein (Investors & Media)
(650) 624-3000
|
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Cytokinetics via Globenewswire
HUG#1921614
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024